The Indo American Journal of Pharmaceutical Research (IAJPR) upholds a stringent stance against plagiarism and any form of unethical duplication. Plagiarism occurs when substantial portions of a manuscript are copied from previously published works. To ensure the integrity of submissions, IJIREM screens all manuscripts using advanced plagiarism detection tools, including DupliChecker, SmallSEOtools, CrossCheck, and Turnitin. If a manuscript is found to contain more than 25% plagiarized content, the authors will be notified and required to revise their submission.

If a manuscript is discovered to have been plagiarized post-publication, the Editor-in-Chief will initiate a preliminary investigation, potentially involving a designated committee. Should the investigation confirm that the manuscript exceeds acceptable plagiarism limits, the paper will be promptly removed from the journal’s website. No claims will be accepted against the publisher or journal thereafter, and the publisher will not be held responsible.

Indo American Journal of Pharmaceutical Research (IAJPR) is committed to upholding intellectual property rights and fostering original research. Manuscripts containing plagiarized content are inconsistent with the journal’s standards of quality and innovation. Therefore, all authors are required to adhere to ethical standards and avoid any form of plagiarism.Should a manuscript be suspected of plagiarism, IAJPR will contact the author(s) to provide an explanation within two weeks. This explanation will be reviewed by the Fact-Finding Committee (FFC), which will determine the subsequent actions. IAJPR reserves the right to disable the author’s account and reject all future submissions for a period of 3, 5, or 10 years, or to impose a permanent ban on the author.